|
1
|
Yang B, Dong K, Guo P, Guo P, Jie G, Zhang
G and Li T: Identification of key biomarkers and potential
molecular mechanisms in oral squamous cell carcinoma by
bioinformatics analysis. J Comput Biol. 27:40–54. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kademani D: Oral cancer. Mayo Clin Proc.
82:878–887. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Joseph JP, Harishankar MK, Pillai AA and
Devi A: Hypoxia induced EMT: A review on the mechanism of tumor
progression and metastasis in OSCC. Oral Oncol. 80:23–32. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim SY, Han YK, Song JM, Lee CH, Kang K,
Yi JM and Park HR: Aberrantly hypermethylated tumor suppressor
genes were identified in oral squamous cell carcinoma (OSCC). Clin
Epigenetics. 11:1162019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chong CE, Lim KP, Gan CP, Marsh CA, Zain
RB, Abraham MT, Prime SS, Teo SH, Silvio Gutkind J, Patel V and
Cheong SC: Over-expression of MAGED4B increases cell migration and
growth in oral squamous cell carcinoma and is associated with poor
disease outcome. Cancer Lett. 321:18–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun C and Li J: Expression of MiRNA-137 in
oral squamous cell carcinoma and its clinical significance. J BUON.
23:167–172. 2018.PubMed/NCBI
|
|
7
|
Qiu YL, Liu YH, Ban JD, Wang WJ, Han M,
Kong P and Li BH: Pathway analysis of a genome-wide association
study on a long non-coding RNA expression profile in oral squamous
cell carcinoma. Oncol Rep. 41:895–907. 2019.PubMed/NCBI
|
|
8
|
Jin T, Guo Y and Huang Z, Zhang Q and
Huang Z, Zhang Y and Huang Z: Vitamin D inhibits the proliferation
of oral squamous cell carcinoma by suppressing lncRNA LUCAT1
through the MAPK pathway. J Cancer. 11:5971–5981. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang X, Yang S, Lv X, Wang L and Li C:
Overexpression of LncRNA SNHG1 were suitable for oncolytic
adenoviruse H101 therapy in oral squamous-cell carcinoma.
OncoTargets Ther. 13:13033–13039. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gullerova M: Long non-coding RNA. Genomic
Elements in Health, Disease and Evolution. Felekkis K and
Voskarides K: Springer; New York, NY: pp. 83–108. 2015, View Article : Google Scholar
|
|
11
|
Cui HB, Ge HE, Wang YS and Bai XY:
MiR-208a enhances cell proliferation and invasion of gastric cancer
by targeting SFRP1 and negatively regulating MEG3. Int J Biochem
Cell Biol. 102:31–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bayarmaa B, Wu Z, Peng J, Wang Y, Xu S,
Yan T, Yin W, Lu J and Zhou L: Association of LncRNA MEG3
polymorphisms with efficacy of neoadjuvant chemotherapy in breast
cancer. BMC Cancer. 19:8772019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Yao T, Wang Y, Yu J, Liu Y and
Lin Z: Long noncoding RNA MEG3 is downregulated in cervical cancer
and affects cell proliferation and apoptosis by regulating miR-21.
Cancer Biol Ther. 17:104–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dykes IM and Emanueli C: Transcriptional
and post-transcriptional gene regulation by long non-coding RNA.
Genom Proteom Bioinf. 15:177–186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vafadar A, Shabaninejad Z, Movahedpour A,
Mohammadi S, Fathullahzadeh S, Mirzaei HR, Namdar A, Savardashtaki
A and Mirzaei H: Long non-coding RNAs as epigenetic regulators in
cancer. Curr Pharm Design. 25:3563–3577. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huarte M: The emerging role of LncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qiu C, Li S, Sun D and Yang S: lncRNA PVT1
accelerates progression of non-small cell lung cancer via targeting
miRNA 526b/EZH2 regulatory loop. Oncol Lett. 19:1267–1272.
2020.PubMed/NCBI
|
|
18
|
Han X, Zheng J, Wang Y and Gao Z: MiRNA
29a inhibits colon cancer growth by regulation of the
PTEN/Akt/GSK3β and Wnt/β catenin signaling pathways. Oncol Lett.
16:2638–2644. 2018.PubMed/NCBI
|
|
19
|
Zheng Z, Li W, Xu J, Xie B, Yang M, Huang
H, Li H and Wang Q: LncMSEN1, a mantle specific LncRNA
participating in nacre formation and response to polyI: C
stimulation in pearl oyster Pinctada fucata martensii. Fish
Shellfish Immunol. 96:330–335. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu S, Wu L, Qi H and Xu M:
LncRNA/circRNA-miRNA-mRNA networks regulate the development of root
and shoot meristems of Populus. Ind Crop Prod. 133:333–347. 2019.
View Article : Google Scholar
|
|
21
|
Gibb EA, Vucic EA, Enfield KS, Stewart GL,
Lonergan KM, Kennett JY, Becker-Santos DD, MacAulay CE, Lam S,
Brown CJ and Lam WL: Human cancer long non-coding RNA
transcriptomes. PLoS One. 6:e259152011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He Q, Long J, Yin Y, Li Y, Lei X, Li Z and
Zhu W: Emerging roles of lncRNAs in the formation and progression
of colorectal cancer. Front Oncol. 9:15422020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo QY, Wang H and Wang Y: LncRNA H19
polymorphisms associated with the risk of OSCC in Chinese
population. Eur Rev Med Pharmacol Sci. 21:3770–3774.
2017.PubMed/NCBI
|
|
24
|
Liu L, Zhan Y, Huang Y and Huang L: LncRNA
FGD5-AS1 can be predicted as therapeutic target in oral cancer. J
Oral Pathol Med. 49:243–252. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun CC, Zhang L, Li G, Li SJ, Chen ZL, Fu
YF, Gong FY, Bai T, Zhang DY, Wu QM and Li DJ: The lncRNA PDIA3P
interacts with miR-185-5p to modulate oral squamous cell carcinoma
progression by targeting cyclin D2. Mol Ther Nucleic Acids.
9:100–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niu X, Yang B, Liu F and Fang Q: LncRNA
HOXA11-AS promotes OSCC progression by sponging miR-98-5p to
upregulate YBX2 expression. Biomed Pharmacother. 121:1096232020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X, Li H and Shi J: LncRNA HOXA11-AS
promotes proliferation and cisplatin resistance of oral squamous
cell carcinoma by suppression of miR-214-3p expression. Biomed Res
Int. 2019:86451532019.PubMed/NCBI
|
|
28
|
Zhou Y, Zhang X and Klibanski A: MEG3
noncoding RNA: A tumor suppressor. J Mol Endocrinol. 48:R45–R53.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang J, Liang Y, Huang X, Guo X, Liu Y,
Zhong J and Yuan J: STAT3-induced upregulation of lncRNA MEG3
regulates the growth of cardiac hypertrophy through
miR-361-5p/HDAC9 axis. Sci Rep. 9:4602019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schuster-Gossler K, Bilinski P, Sado T,
Ferguson-Smith A and Gossler A: The mouse GTL2 gene is
differentially expressed during embryonic development, encodes
multiple alternatively spliced transcripts, and may act as an RNA.
Dev Dyn. 212:214–228. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takahashi N, Okamoto A, Kobayashi R,
Shirai M, Obata Y, Ogawa H, Sotomaru Y and Kono T: Deletion of
GTL2, imprinted non-coding RNA, with its differentially methylated
region induces lethal parent-origin-dependent defects in mice. Hum
Mol Genet. 18:1879–1888. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou Y, Cheunsuchon P, Nakayama Y, Lawlor
MW, Zhong Y, Rice KA, Zhang L, Zhang X, Gordon FE, Lidov HG, et al:
Activation of paternally expressed genes and perinatal death caused
by deletion of the GTL2 gene. Development. 137:2643–2652. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stadtfeld M, Apostolou E, Akutsu H, Fukuda
A, Follett P, Natesan S, Kono T, Shioda T and Hochedlinger K:
Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse
induced pluripotent stem cells. Nature. 465:175–181. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kaneko S, Bonasio R, Saldaña-Meyer R,
Yoshida T, Son J, Nishino K, Umezawa A and Reinberg D: Interactions
between JARID2 and noncoding RNAs regulate PRC2 recruitment to
chromatin. Mol Cell. 53:290–300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wei GH and Wang X: lncRNA MEG3 inhibit
proliferation and metastasis of gastric cancer via p53 signaling
pathway. Eur Rev Med Pharmacol Sci. 21:3850–3856. 2017.PubMed/NCBI
|
|
36
|
Hu D, Su C, Jiang M, Shen Y, Shi A, Zhao
F, Chen R, Shen Z, Bao J and Tang W: Fenofibrate inhibited
pancreatic cancer cells proliferation via activation of p53
mediated by upregulation of LncRNA MEG3. Biochem Biophys Res
Commun. 471:290–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao Y and Hong L: lncRNA-PRLB confers
paclitaxel resistance of ovarian cancer cells by regulating
RSF1/NF-κB signaling pathway. Cancer Biother Radiopharm.
36:202–210. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao H, Zheng GH, Li GC, Xin L, Wang YS,
Chen Y and Zheng XM: Long noncoding RNA LINC00958 regulates cell
sensitivity to radiotherapy through RRM2 by binding to
microRNA-5095 in cervical cancer. J Cell Physiol. 234:23349–23359.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Al-Rugeebah A, Alanazi M and Parine NR:
MEG3: An oncogenic long non-coding RNA in different cancers. Pathol
Oncol Res. 25:859–874. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li X, Zhao J, Geng J, Chen F, Wei Z, Liu
C, Zhang X, Li Q, Zhang J, Gao L, et al: Long Non-Coding RNA MEG3
knockdown attenuates endoplasmic reticulum stress-mediated
apoptosis by targeting p53 following myocardial infarction. J Cell
Mol Med. 23:8369–8380. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Uroda T, Anastasakou E, Rossi A, Teulon
JM, Pellequer JL, Annibale P, Pessey O, Inga A, Chillón I and
Marcia M: Conserved pseudoknots in lncRNA MEG3 are essential for
stimulation of the p53 pathway. Mol Cell. 75:982–995.e9. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang LL, Hu D and Zou LH: Low expression
of lncRNA MEG3 promotes the progression of oral squamous cell
carcinoma by targeting miR-21. Eur Rev Med Pharmacol Sci.
22:8315–8323. 2018.PubMed/NCBI
|
|
44
|
Dong Z, Zhang A, Liu S, Lu F, Guo Y, Zhang
G, Xu F, Shi Y, Shen S, Liang J and Guo W: Aberrant
methylation-mediated silencing of lncRNA MEG3 functions as a ceRNA
in esophageal cancer. Mol Cancer Res. 15:800–810. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Molina-Pinelo S, Salinas A, Moreno-Mata N,
Ferrer I, Suarez R, Andrés-León E, Rodríguez-Paredes M, Gutekunst
J, Jantus-Lewintre E, Camps C, et al: Impact of DLK1-DIO3 imprinted
cluster hypomethylation in smoker patients with lung cancer.
Oncotarget. 9:4395–4410. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hill KE, Kelly AD, Kuijjer ML, Barry W,
Rattani A, Garbutt CC, Kissick H, Janeway K, Perez-Atayde A,
Goldsmith J, et al: An imprinted non-coding genomic cluster at
14q32 defines clinically relevant molecular subtypes in
osteosarcoma across multiple independent datasets. J Hematol Oncol.
10:1072017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang J, Lin Z, Gao Y and Yao T:
Downregulation of long noncoding RNA MEG3 is associated with poor
prognosis and promoter hypermethylation in cervical cancer. J Exp
Clin Cancer Res. 36:52017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao Y, Huang P and Zhang J:
Hypermethylation of MEG3 promoter correlates with inactivation of
MEG3 and poor prognosis in patients with retinoblastoma. J Transl
Med. 15:2682017. View Article : Google Scholar : PubMed/NCBI
|
